Welcome to our dedicated page for Repare Therapeutics news (Ticker: RPTX), a resource for investors and traders seeking the latest updates and insights on Repare Therapeutics stock.
Repare Therapeutics Inc. was a clinical-stage precision oncology company whose updates centered on oncology drug programs, portfolio partnerships, and corporate-status developments. Recurring news included clinical disclosures for RP-1664, an oral PLK4 inhibitor studied in TRIM37-high solid tumors in the LIONS trial, and RP-3467, a Polθ ATPase inhibitor evaluated in the POLAR trial. Other updates covered the lunresertib PKMYT1 inhibitor license, out-licensing of discovery platforms, operating results, capital-structure matters, governance, and the completed acquisition and related delisting process.
Repare Therapeutics (Nasdaq: RPTX), a clinical-stage precision oncology company, announced that its senior management will participate in the Goldman Sachs 45th Annual Global Healthcare Conference.
The event will take place on June 10, 2024, at 2:40 p.m. Eastern Time in Miami, FL. The session will include a fireside chat, and a live webcast will be available on Repare's investor relations website.
The webcast replay will be accessible for 90 days post-event.
Repare Therapeutics (Nasdaq: RPTX) announced that initial data from its Phase 1 MINOTAUR study will be presented at the European Society of Medical Oncology (ESMO) GI Congress 2024. The study evaluates the efficacy of lunresertib (RP-6306) in combination with FOLFIRI for treating advanced solid tumors. This presentation is scheduled for June 27, 2024, at 3:35 PM CEST in Munich, Germany. The study aims to offer new insights into advanced gastrointestinal cancer treatments.
Repare Therapeutics Inc. reported financial results for Q1 2024, highlighting clinical progress in various programs. FDA agrees with RP2D for lunresertib plus camonsertib combo. Phase 2 TRESR expansion and Phase 1 LIONS monotherapy trial initiated. $237.0M in cash to fund operations till mid-2026. Camonsertib rights regained, new trial initiations, and board appointment announced. Revenue from collaboration agreements increased to $52.4M. Net income for Q1 2024 was $13.2M.
Repare Therapeutics and Debiopharm have dosed the first patient in the Phase 1/1b MYTHIC trial, evaluating the combination of PKMYT1 and WEE1 inhibition. This collaboration aims to assess safety, pharmacokinetics, and preliminary clinical activity of lunresertib and Debio 0123, showing promise for cancer patients.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.